Erick DeVinney - 16 Mar 2025 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role: Chief Innovation Officer
Signature: /s/Erick DeVinney
Issuer symbol: AXGN
Transactions as of: 16 Mar 2025
Transactions value $: -$264,443
Form type: 4
Filing time: 19 Mar 2025, 17:24:10 UTC
Previous filing: 04 Mar 2025
Next filing: 26 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AXGN	Common Stock	Options Exercise	$0	+2.95K	+1.47%	$0.00	203K	16 Mar 2025	Direct	F1
transaction	AXGN	Common Stock	Options Exercise	$0	+6.36K	+3.13%	$0.00	210K	16 Mar 2025	Direct	F1
transaction	AXGN	Common Stock	Options Exercise	$0	+23.2K	+11.04%	$0.00	233K	16 Mar 2025	Direct	F1
transaction	AXGN	Common Stock	Sale	-$264K	-15.1K	-6.49%	$17.50	218K	19 Mar 2025	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AXGN	Restricted Stock Units	Options Exercise	$0	-2.95K	-100%	$0.00	0	16 Mar 2025	Common Stock	2.95K		Direct	F4, F5
transaction	AXGN	Restricted Stock Units	Options Exercise	$0	-6.36K	-50%	$0.00	6.36K	16 Mar 2025	Common Stock	6.36K		Direct	F4, F6
transaction	AXGN	Restricted Stock Units	Options Exercise	$0	-23.2K	-50%	$0.00	23.2K	16 Mar 2025	Common Stock	23.2K		Direct	F4, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This reflects the number of restricted stock units that became vested as of March 16, 2025.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 16, 2025. This sale does not represent a discretionary trade by the Reporting Person.
F3	The reported price in Column 4 is a weighted average sale price. These shares were sold on March 19, 2025 in multiple transactions at $17.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4	Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F5	All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
F6	All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F7	All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.